The Selenazal Drug Ebselen Potently Inhibits Indoleamine 2,3-Dioxygenase by Targeting Enzyme Cysteine Residues
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The heme enzyme indoleamine 2,3-dioxygenase (IDO) plays an important immune regulatory role by catalyzing the oxidative degradation of l-tryptophan. Here we show that the selenezal drug ebselen is a potent IDO inhibitor. Exposure of human macrophages to ebselen inhibited IDO activity in a manner independent of changes in protein expression. Ebselen inhibited the activity of recombinant human IDO (rIDO) with an apparent inhibition constant of 94 +/- 17 nM. Optical and resonance Raman spectroscopy showed that ebselen altered the active site heme of rIDO by inducing a transition of the ferric heme iron from the predominantly high- to low-spin form and by lowering the vibrational frequency of the Fe-CO stretch of the CO complex, indicating an opening of the distal heme pocket. Substrate binding studies showed that ebselen enhanced nonproductive l-tryptophan binding, while circular dichroism indicated that the drug reduced the helical content and protein stability of rIDO. Thiol labeling and mass spectrometry revealed that ebselen reacted with multiple cysteine residues of IDO. Removal of cysteine-bound ebselen with dithiothreitol reversed the effects of the drug on the heme environment and significantly restored enzyme activity. These findings indicate that ebselen inhibits IDO activity by reacting with the enzyme's cysteine residues that result in changes to protein conformation and active site heme, leading to an increase in the level of nonproductive substrate binding. This study highlights that modification of cysteine residues is a novel and effective means of inhibiting IDO activity. It also suggests that IDO is under redox control and that the enzyme represents a previously unrecognized in vivo target of ebselen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341 · cited 2×
“Indoleamine 2,3-dioxygenase (IDO)(1) is a 42-45 kDa intracellular, heme enzyme that catalyzes the initial and rate-limiting step of L-tryptophan (L-Trp) metabolism along the kynurenine pathway (1-3).”
BackgroundMethodMuller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005) · Nature Medicine · doi:10.1038/nm1196 · Cited by 1,064 · cited 2×
“In light of the evidence of IDO expression contributing to a pathological state of immune tolerance toward certain tumorassociated antigens, there is growing interest in the discovery of potent small molecule inhibitors of IDO activity, as such agents may represent effective adjuvants for traditional chemotherapeutic…”
BackgroundEbselen, a Glutathione Peroxidase Mimetic Seleno-organic Compound, as a Multifunctional Antioxidant
Nakamura, Y., Feng, Q., Kumagai, T., Torikai, K., Ohigashi, H., Osawa, T., Noguchi, N., Niki, E., & Uchida, K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109641200 · Cited by 161 · cited 1×
“One of the effective agents was the seleno-organic compound ebselen [2-phenyl-1,2-benzisoselenazol-3(2H)-one (Figure 1)] that exhibits low toxicity and possesses anti-inflammatory and anti-atherosclerotic properties in vivo (12-15).”
Background
Cited by
Maes, M., Galecki, P., Chang, Y. S., & Berk, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.05.004 · Cited by 1,140
Maes, M., Leonard, B. E., Myint, A. M., Kubera, M., & Verkerk, R. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.12.017 · Cited by 700
Kynurenines in the CNS: recent advances and new questions
Vécsei, L., Szalárdy, L., Fülöp, F., & Toldi, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3793 · Cited by 641
Ebselen, a promising antioxidant drug: mechanisms of action and targets of biological pathways
Azad, G. K., & Tomar, R. S. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3417-x · Cited by 343
Indoleamine 2,3-Dioxygenase: Is It an Immune Suppressor?
Soliman, H., Mediavilla-Varela, M., & Antonia, S. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eb3343 · Cited by 184
Rational Design of 4-Aryl-1,2,3-Triazoles for Indoleamine 2,3-Dioxygenase 1 Inhibition
Röhrig, U. F., Majjigapu, S. R., Grosdidier, A., Bron, S., Stroobant, V., Pilotte, L., Colau, D., Vogel, P., Van den Eynde, B. J., Zoete, V., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300260v · Cited by 170
Metadata
- Authors
- Terentis, A. C., Freewan, M., Sempértegui Plaza, T. S., Raftery, M. J., Stocker, R., & Thomas, S. R.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2009-12-23
- Volume
- 49
- Issue
- 3
- Pages
- 591-600
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2093917686
- Cited by
- 93
- References
- 3
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.